Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 111 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MYXGeY5kfGmxbjDBd5NigQ>? MljlNE44|ryP NYHmdnI1OjSq NYDtZXlx\XSqYX7vcC=> MXvlcohidmOnczDFUoFEKGGlZYT5cIF1cW:wIHHu[EBqdmO{ZXHz[ZMhTU6jQzDhZpVv\GGwY3WgbY4hfGinIITveIFtKGOnbHygcJl{[XSnIHHu[EBifCC2aHWgZ4VtdCC|dYLmZYNm M37WWFI2Pzh5MEe5
TE13 MXLGeY5kfGmxbjDBd5NigQ>? M2X0[FAvO87:TR?= M{f3NFI1cA>? MV\1dE1z\We3bHH0[ZMhWkGVU1[1RUBt\X[nbB?= M2PlTFI2PTd7Nk[1
TE13 M1SxfGFxd3C2b4Ppd{BCe3OjeR?= NH7NZW8xNjQQvF2= MnX2NlRp MoPobY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? MlTtNlU2Pzl4NkW=
MEFs M4LhdmZ2dmO2aX;uJGF{e2G7 MlXiOe69VQ>? NXTBdFV6OT[q M4TrR4lv[3KnYYPld{B1cGViRWDFR{BifHSjY3jt[Y51NCCWaYKg[IVtcX[ncomgZY5lKHSqZTDl[oZq[2mnbnP5JI9nKHCnZHXzeIFtKG[xcn3heIlwdg>? MkjkNlU1QDJ4M{S=
SW480  NV;3SHpiTnWwY4Tpc44hSXO|YYm= MYmwMlHPxE1? MmC0OFhp NWPoOYp[TE2VTx?= M2G0eJJmfmW{c3XzJGVOXA>? M{DsSFI2PDN2OUm3
PC3  M3fYNGZ2dmO2aX;uJGF{e2G7 NFnuSYUxNjIQvF2= NX3KfXFjPDiq MX3EUXNQ NXrDUpBDemW4ZYLz[ZMhTU2W NVj3THFbOjV2M{S5PVc>
SW480  NETIdZpHfW6ldHnvckBCe3OjeR?= M3nnO|AvOc7:TR?= MoHoOFhp Ml7SSG1UVw>? NWLmOVhI[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u MlLKNlU1OzR7OUe=
PC3  M2XUPWZ2dmO2aX;uJGF{e2G7 NYTETnJuOC5zzszN NXTSTYJZPDiq NFW4eZBFVVOR NGK3fGZifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= MkO1NlU1OzR7OUe=
SW480  Ml\VSpVv[3Srb36gRZN{[Xl? NYHJbow4OC5zzszN NX3ES25rPDiq MVzEUXNQ M3O3d4lv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? NV;SVnFIOjV2M{S5PVc>
PC3  M4XDemZ2dmO2aX;uJGF{e2G7 MnfXNE4y|ryP NET3T2Q1QGh? M17hZ2ROW09? M1\z[4lv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? NYnMU2JIOjV2M{S5PVc>
A431 M4HGV2Fxd3C2b4Ppd{BCe3OjeR?= NGi5WlEzNzFyL{WwM|ExOG6P MXq0PIg> MmOzSG1UVw>? NX\kWm9HcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To MXWyOVM4OTB4OR?=
A431 M2i1WmZ2dmO2aX;uJGF{e2G7 MYW1NI5O MmPLNk83NzF{L{K0bC=> M1n1RmROW09? NUDYdVFG[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO|aX;u NYr1PXdHOjV|N{GwOlk>
MDA-MB-231 M1T0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGmxVGgxNTZyMH7N MkXNNlRp NX[yXZFpTE2VTx?= MnXLTWM2OCCxZjCxNFBvVQ>? NGr2UIgzPTF7MkeyNS=>
MCF7 NWm2e|JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmwMVYxOG6P NYTxOpZwOjSq MlvJSG1UVw>? NE\MboFKSzVyIH;mJFc2dk1? MV[yOVE6Ojd{MR?=
SKOV-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fBWlEuOTEQvF2= MVmyOIg> NVTTXpdtTE2VTx?= Mn7zTWM2OCCxZjC1MlbPxE1? MWeyOVE3QTR7MR?=
A549 MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYexMVEx|ryP NVnFOoZvOjSq MlnnSG1UVw>? MnvqTWM2OCCxZjCzMlLPxE1? NEXUcIMzPTF4OUS5NS=>
SKOV-3 NVjDWYtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:3UmoxNjFvMd88US=> NHrvfGo1QGh? NU\uVXZVTE2VTx?= MXTJR|UxKG:oIECuO:69VQ>? M4fzc|I2OTZ7NEmx
A549 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWiwMlEuOc7:TR?= NHHjfFI1QGh? MUHEUXNQ MYnJR|UxKG:oIECuNljPxE1? M3:1OVI2OTZ7NEmx
SKOV-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HrZlAvODFvMD65{txO MnTOO|Jp NX33U4NFTE2VTx?= M1X4c2lEPTBib3[gNE4{Os7:TR?= M1XtU|I2OTZ7NEmx
A549 M2L4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLCXVcxNjBzLUCuPe69VQ>? MoPSO|Jp NHLBUm9FVVOR MVTJR|UxKG:oIECuNFbPxE1? MkD0NlUyPjl2OUG=
HeLa NVqwR3JtTnWwY4Tpc44hSXO|YYm= MYqyOVBvVQ>? MWixOog> MlroSG1UVw>? MYXpcoNz\WG|ZYOgR3lROUFzIH3SUmEh\XiycnXzd4lwdsLi Mk\sNlUyOTZ4OEi=
CNE2 NY[yTZA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLuNVAxNTZyMH7N M4PqW|I1NzR6L{eybC=> M2\4SYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFHKbWkzPDl4OUmwNS=>
PC3 Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDGNVAxNTFyMEDuUS=> M2rIUlI1cA>? MWjJR|UxKG:oIEOwNI5O MlrQNlQ5PTR4NUi=
LNCaP MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTPSnhOOTByLUGwNFBvVQ>? M4LuclI1cA>? MkLTTWM2OCCxZjCzNFBvVQ>? NUPDSHlkOjR6NUS2OVg>
HeLa  NWHJc3RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPwSIoz|ryP NX22Xms{PDiq NInnSGFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl NV\zSng5OjR6NE[xN|U>
HMEC-1  MXnGeY5kfGmxbjDBd5NigQ>? MnvzN|Axdk1? M{C2dFI1cA>? MnzZbY5kemWjc3XzJIV5eHKnc4Ppc44hd2cEoG\FS2ZTO8LibWLORS=> MUmyOFcyODZ|MR?=
HeLa NGjBeYVHfW6ldHnvckBCe3OjeR?= MYexcW0> MXqwMlVp MmP1ZYJwdGm|aHXzJJRp\SC2b4ThcEBJTEGFIHHjeIl3cXS7 MonnNlQ4ODd2N{S=
ACP02 M2TLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTUNlUxNzN3MD:1NFBvVQ>? NXjl[WdEOjSq NULqTJl7\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= MV:yOFY3QDV2Nx?=
ACP03 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjUZ5VQOjVyL{O1NE82ODCwTR?= M1y0clI1cA>? NVfkOZUz\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= MUSyOFY3QDV2Nx?=
U87 GBM MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLvNVAxNzNyMD:1NFAhdk1? MmnQO|IhcA>? M174V|ExOCViZYToZY5wdA>? M1e0V5Jm\HWlZYOgcYVidiClZXzsJI52dWKncjDifUA{OSxiNUSsJIFv\CB3ONMgKS=> Mkm0NlQ1PjR6NEG=
U87 GBM NYDTc2x[TnWwY4Tpc44hSXO|YYm= Ml3wNVAxNzVyMDDOcS=> MV60PEBp MoXaNVAxLSCndHjhco9t MWnJcoR2[2W|IGPlcoV{[2WwY3WtUIls\SCDbITldoF1cW:wczDpckBPfWOuZXHyJG1wenCqb3zv[5k> M{W1dVI1PDZ2OESx
RPE NGjDT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvjRXkzOC5{L{CuOE8xNjhxMTFOwG0> M2TqNlI1NzR6L{eyJIg> MVfEUXNQ MkDnbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gZpkh[2WubDDjfYNt\SCjcoLld5Q> NVrzVZE{OjR2NU[2NFI>
HT29  NH7tSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X6TFE5OCCwTR?= NXq0N5prPzJiaB?= NIPTR5pKSzVyIH;mJFE5OCCwTR?= NH[2RpEzPDN4OEK2OS=>
hMSCs NYPCNGs4TnWwY4Tpc44hSXO|YYm= MVi2MlI2KG6P NVPIfHpqOjRiaB?= M3;tcWROW09? MUXzeIFjcWyrenXzJGhqe3SxbnWgRYNmfHmuYYTpc44h[W6mIITo[UBGgHC{ZYPzbY9vKG:oIGDseZJqeG:2ZX70JGdmdmW| NHm5SnozPDNzMkO1Oi=>
Huh7  MXPGeY5kfGmxbjDBd5NigQ>? NEHwR4wxNjFxMD61M|EvOCEQvF2= Mo\GNlRp Ml7rd5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w NF3DRVYzPDJ4OU[3Ni=>
SKOV3 NF33cGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXZemoxNjB3LUKg{txO NUHlfox7OTBxMkSvOFghcA>? MnHzSG1UVw>? NV;w[VRLdWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MlTBNlQzOjN6MEG=
A2780 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[wMlA2NTJizszN NYfj[4lYOTBxMkSvOFghcA>? MWDEUXNQ NHTHbG1u\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NX3kb|cxOjR{MkO4NFE>
SRA01/04  M3;YbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULTeYlROC5{IN88US=> NYr5eoc1PDhiaB?= Ml7JSG1UVw>? MkPsd5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> NEHNdG4zPDF3N{i3PC=>
HLEB3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT5fnUxNjJizszN MXS0PEBp NWjlRpp[TE2VTx?= MXPzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> M{\pelI1OTV5OEe4
SRA01/04  MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfLNE41NzBwODFOwG0> M3m3R|Q5KGh? NYfkUHFNTE2VTx?= M1HVdIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NVWyUZpiOjRzNUe4O|g>
HLEB3 M1TEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjUfGxoOC52L{CuPEDPxE1? MVi0PEBp NHLOcIJFVVOR MmnMbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MkfHNlQyPTd6N{i=
HCT116 NX3L[YwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfUNE4zKM7:TR?= MkPvNVIhcA>? NUXT[Hp2\W6qYX7j[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBz[WSrYYTpc44> M2jUT|I1OTJ{MkOx
CA46 NVHlV2FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLDWVMxOy94L{GyM|I1NzR6IH7N MV[0PEBp M2rEU4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB? MXKyOFA3PDl3MR?=
PMNs MnvDSpVv[3Srb36gRZN{[Xl? Mo\aN|Ahdk1? MkLrOFghcA>? NWnRU|dVcW6qaXLpeJMh\W[oZYLvZ5l1d3OrczygTGRCSyCjY4Tpeol1gSCjbnSgVoFkKGGldHn2bZR6 MUSyN|k5QDZzNx?=
H1299 M{H5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxxsDPxE4EoB?= M1rJOVI1NzR6L{eyJIg> MofO[ZRp[W6xbB?= NIjaRY9qdmO{ZXHz[ZMh[2WubDDk[YF1cCCjZoTldkAzPGh? MYCyN|kyPjZyOR?=
A549 M3\hfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV6wMlI2NzBwNT:xJO69VQ>? NV61cpN1OjRxNEivO|IhcA>? MVrleIhidm:u NEjYZnNqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NHvrTVAzOzh4N{m5NS=>
H1299 NFS3fIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3McpRvOC5{NT:wMlUwOSEQvF2= NYDxPXNnOjRxNEivO|IhcA>? NFf3R5ZmfGijbn;s NHHQPZBqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M3[wR|I{QDZ5OUmx
A549 MmPSRZBweHSxc3nzJGF{e2G7 MkXzNE42NzFizszN MX60PEBp MoXl[ZRp[W6xbB?= M{fMTYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NXjLOldUOjN6Nke5PVE>
H1299 MoqzRZBweHSxc3nzJGF{e2G7 NFPOTpUxNjVxMTFOwG0> MnHJOFghcA>? NYjHdpZT\XSqYX7vcC=> M4PQcolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NWjYXlNlOjN6Nke5PVE>
SUM149PT MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS1SnAzNzdwNT:xNEDPxE1? MlfZOFghcA>? MWfEUXNQ MYLpcoR2[2W|IHPlcIwh\GWjdHigZZQhOiEQvF2gbY5{\W6|aYTpeoVtgQ>? NWKxdJIzOjN5OUK2N|g>
SUM190PT NEX3bJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jZVVUxNzFyMD:yOVAhdk1? MlS3OFghcA>? Mn;ISG1UVw>? MlXQbY5lfWOnczDj[YxtKGSnYYToJIF1KDVyIH7NJJNmdnOrdHn2[Yx6 NGnBOnEzOzd7Mk[zPC=>
HCT1 NV3x[IQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvtNE4zNzFwMD:1MlAh|ryP MkfyNVIwOjRxM{[vOFghcA>? NYT0dZg4cW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NXnpdHJ6OjN5N{CwNFA>
Lovo MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzVTmgxNjJxMT6wM|UvOCEQvF2= MmLSNVIwOjRxM{[vOFghcA>? MV3pcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M3rWUFI{PzdyMECw
AGS MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[5NE4xOTVvMTFOwG0> NGPBe3Q4OiCq MnOzbY5lfWOnczDj[YxtKGSnYYToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= NWS1fZJ[OjN5NEWwNlQ>
Huh7 MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW2PJYyKM7:TR?= M3LY[FI1KGh? MXvEUXNQ NILIUplz\WS3Y3XzJIFjd3W2IEKwKUB3cWGkaXzpeJnDqA>? NXe3T|hZOjN4NEO5N|M>
ECC1 NV63XIl6TnWwY4Tpc44hSXO|YYm= MWq1NFAhdk1? Mn3EOUBl MVHEUXNQ NEXqVoZqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NEnFNHIzOzV|MEe2PS=>
HEC1A M2\4N2Z2dmO2aX;uJGF{e2G7 NWnUOIdKPTByIH7N M{nqbFUh\A>? NYDCNGttTE2VTx?= NVnhVpRPcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= NVfBOG92OjN3M{C3Olk>
EN1 NU\kUog{TnWwY4Tpc44hSXO|YYm= MYm1NFAhdk1? MYO1JIQ> MYfEUXNQ M37qdYlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NFPENJMzOzV|MEe2PS=>
MFE296 MVfGeY5kfGmxbjDBd5NigQ>? MVm1NFAhdk1? NWHNU2xGPSCm MXjEUXNQ MnLDbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NHSy[IUzOzV|MEe2PS=>
HASMCs M1HQZWZ2dmO2aX;uJGF{e2G7 MoriNE02ODBibl2= NGfLRmc3KGR? NIH4WY1ld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDIRWREKGGwZDDj[YxtKH[rYXLpcIl1gQ>? M3noflI{PTF6NE[3
U373 M2Xt[mZ2dmO2aX;uJGF{e2G7 M1vkbVAvOjVxMD61M|Eh|ryP NXrvd25EOjRiaB?= NHvqV2ZqdmO{ZXHz[ZMhWFJvQjDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFVCgmGmQx?= MX2yN|Q4PDF5MR?=
ARN8  MULGeY5kfGmxbjDBd5NigQ>? MWKwMlA2NTJizszN MYGyOEBp MnnkdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> NHPWZZkzOzR5MEW0NC=>
MCF7 M{P6TGZ2dmO2aX;uJGF{e2G7 NI\5WpUxNjB3LUKg{txO M4XLbFI1KGh? NITmR|Jz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? M4DneFI{PDdyNUSw
H1299  MmDsSpVv[3Srb36gRZN{[Xl? NXXWW|VROC5|M,MAl|HDqML3TR?= NVy5NnZKOjRxNEigbC=> Mn62SG1UVw>? MnqzbY5kemWjc3XzJGUu[2GmaHXybY4heHKxdHXpckBt\X[nbIOg[I9{\SCmZYDlcoRmdnSueR?= NFi4[XQzOzR4MUm3OS=>
H1299 MXLGeY5kfGmxbjDBd5NigQ>? MUOwMlUh|ryP MmPHOFghcA>? M3Ky[WROW09? M1S0TolvcGmkaYTzJJRp\SCvaXfyZZRwenlicH;0[Y51cWGuIHPvcYJqdmVid3n0bEB{cWyrYnnubY4> M3\HXlI{PDZzOUe1
H1299 MYLGeY5kfGmxbjDBd5NigQ>? MmeyNE42KM7:TR?= MnjuOFghcA>? Mn:2SG1UVw>? MUDpcohq[mm2czD0bIUhcW64YYPpeoVv\XO|wrCgZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? MnX3NlM1PjF7N{W=
MG-63  M375OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvQR21ZOC5|IN88US=> NWDIR4puOTJvOU[gbC=> NH;NUXVFVVOR MVLpcohq[mm2czD0bIUh[2WubDDndo94fGhiY3:teJJm[XSvZX70JJdqfGhibXX0[o9zdWmw NX7hNmN{OjN2NUG4NVc>
LM8 Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:wMlMh|ryP MnrXNVIuQTZiaB?= MUnEUXNQ MnjHbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= NVTS[mhqOjN2NUG4NVc>
K562 M{XTb2Z2dmO2aX;uJGF{e2G7 MV[wMlUh|ryP NYP1XJZKOjRiaB?= MXvleIhidm:u MkXw[IVkemWjc3XzJJRp\SCnbor5cYUh[WO2aY\peJkhd2ZiSFTBR5Mh[29vdILlZZRu\W62IIfpeIgh[3W{Y4XtbY4> M3jk[VI{PDNyOUW3
HEL M4n0e2Z2dmO2aX;uJGF{e2G7 NWPObGlsOC53IN88US=> NUPRWlF5OjRiaB?= NX;3S2FP\XSqYX7vcC=> NYrm[ldn\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? MVSyN|Q{ODl3Nx?=
HL60 NGj4U4hCeG:ydH;zbZMhSXO|YYm= NV;BN2FzOSEQvF2= NXHBfG1XOjRiaB?= MnO1bY5lfWOnc9MgZ4VtdCCmZXH0bC=> MnrlNlM1ODB3MUm=
KG1 MXLBdI9xfG:|aYOgRZN{[Xl? MlnHNUDPxE1? NV7oSHdlOjRiaB?= MomybY5lfWOnc9MgZ4VtdCCmZXH0bC=> MmXBNlM1ODB3MUm=
Kazumi MoLtRZBweHSxc3nzJGF{e2G7 MXOxJO69VQ>? NVnCelhkOjRiaB?= MnrSbY5lfWOnc9MgZ4VtdCCmZXH0bC=> NVP6bZFpOjN2MEC1NVk>
K562 NVT2XmZISXCxcITvd4l{KEG|c3H5 M{HZ[VEh|ryP MYqyOEBp Moe4bY5lfWOnc9MgZ4VtdCCmZXH0bC=> MmHnNlM1ODB3MUm=
THP1 MXXBdI9xfG:|aYOgRZN{[Xl? M4THUVEh|ryP MXyyOEBp M{Hxfolv\HWlZYRCpINmdGxiZHXheIg> MVeyN|QxODVzOR?=
SH-SY5Y MoPoSpVv[3Srb36gRZN{[Xl? MlK3NlUxKG6P NEfGWo0yPiCq Ml;nZ4hidmenczDlfJBz\XO|aX;uJJBifHSncn6gc4Yh\2WwZYOgbY53d2y4ZXSgbY4h[2ixbHXzeIVzd2xic4nueIhme2m|LDD1dJRic2ViYX7kJIVn\my3eB?= MkHwNlM{OjZ2MkK=
HEK293 M17rbGZ2dmO2aX;uJGF{e2G7 Mn7vNUDDvU4EoB?= MUmxPEBpyqB? MkHUbY5pcWKrdIOgeIhmKGujbHnybY4uPy2vZXTpZZRm\CC{ZXPyeYl1dWWwdDDv[kB{gW6yaHnsbY4uOSCjZ3fy[YdifGW|IHnueI8h[WepcnXzc41mew>? NGjTPZMzOzJ6NEi0PC=>
HTK NUKzRpp7TnWwY4Tpc44hSXO|YYm= NH[y[FQ1ODBibl2= M3;4UVczKGh? NF;hfZVqdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v NE\YNIgzOzJ6NECwNi=>
HTK MVTGeY5kfGmxbjDBd5NigQ>? NIXuem0yODBvOECwcm0> MUW3NkBp NWr5SG9{[myxY3vzJHRITi4QsvMAl2lv\HWlZXSgVm9UKGGwZDDINm8zyqCDY3P1cZVt[XSrb36= NHy2NnEzOzJ6NECwNi=>
Caco-2  NFTPcFFHfW6ldHnvckBCe3OjeR?= M1K0SlEhyrWPwrC= MXqyOEBp MXTk[YNz\WG|ZYOgV2VTXCCycn;0[YlvKGW6cILld5Nqd25? MWiyN|E6PTB5MB?=
HeLa M1Lzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z1RlExOCCwTR?= NX30SpROOjRiaB?= MWnEUXNQ M4fGZmlEPTBib3[gNVAxdk1? NFvnToMzOzF4NUe0PC=>
HeLa MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XnOFQxKG6P MUS0PEBp M{HCfGROW09? NF\vN21KSzVyIH;mJFQxdk1? NYLr[JZ[OjNzNkW3OFg>
HeLa NEXPZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\FbFVsOjBibl2= MmDhO|IhcA>? NXvOR4JXTE2VTx?= MWfJR|UxKG:oIEKwcm0> MWWyN|E3PTd2OB?=
HeLa MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfYN|g6OTBxM{CvOVAhdk1? NUfaNnp5PzJiaB?= NFvPfXdFVVOR NV\ico5NcW6lcnXhd4V{KHSqZTDueY1j\XJib3[gUW1RKCkQlN8ocUkhdG:|czDj[YxteyCmb4PlJIRmeGWwZHXueIx6 M1nQU|I{OTZ3N{S4
MDA-MB-231 NF;GN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGyOU01ODBibl2= NVnC[ppEPDhiaB?= NH\qZpVKSzVyIH;mJFI3Oy5{bl5CpC=> MUeyN|A2PTF7OB?=
MCF-7  M4m2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\vNlUuPDByIH7N NH;vTZk1QCCq NEjiWIFKSzVyIH;mJFIzOC52bl2= MVGyN|A2PTF7OB?=
ECC-1  NUTXW4Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K5RlExOCCwTR?= M{nzUlI1KGh? NGHZ[pNmfGijbn;s MoTvbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn MmX1NlMxOjh6MEO=
HEC-1A NUm0cHRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnYcI9JOTByIH7N MVOyOEBp NULMTnBl\XSqYX7vcC=> M2XT[Ilv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?= MlvBNlMxOjh6MEO=
NHAC-kn M1fuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS4d2N2OTBxMUCwM|UxOCCwTR?= MXGxNkBp M3LXVmROW09? M1:1emlEPTBib3[gOVAxdk1? MX2yN|AyPzh5MR?=
A549 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrpNlUxKG6P NV:5bZk{Pi15MjDo MnfuSG1UVw>? M2jXSINifXOnczDhJIdz\WG2ZYKgbY5pcWKrdH;yfUBm\m[nY4SgZ49u[mmwZTD3bZRpKFS[VDDvdkBmemyxdHnubYI> NUTCdFVXOjJ7OUS3PFA>
MG-63 MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGzNFAhdk1? NV\1OZlyOTJiaB?= NIK3XVVFVVOR Mn24bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFg3LQ>? M2TJclIzPzl7M{O4
MG-63 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL5SJY{ODBibl2= M4PZZ|I1KGh? MmrWSG1UVw>? MUDpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOlcm M1\4V|IzPzl7M{O4
MG-63 NFH6dXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETKNnU{ODBibl2= NHztVXY1QCCq MnG3SG1UVw>? M3HacYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A2PiV? MVuyNlc6QTN|OB?=
HL60  MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjQSYV6OTVyLUO1NEBvVQ>? NHL2e2YzPCCq M4TPO4lv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> NGfuSpozOjd3M{ezPS=>
U937 M2XURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fOS|E2OC1|NUCgcm0> Mn;wNlQhcA>? MYTpcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N MXKyNlc2Ozd|OR?=
SCC-6 NIrJ[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnsNlAxNTN{MECgcm0> MlPBNVIwOjRxNEigbC=> Mk[zSG1UVw>? MWHpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M{Ll[lIzPTV{M{Kx
U87  NIO4bJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr0fI0yODBvM{CwJI5o NV6xfotNOjRiaB?= NELCVpdqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= M2TTfFIzOjdyOES5
K562 MnnLSpVv[3Srb36gRZN{[Xl? M4O3bVEh|ryP NF;tc3oyOiCq MmL4SG1UVw>? M{nPZYVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS MVuyNlE4QTF7OB?=
Reh M1XmOmZ2dmO2aX;uJGF{e2G7 NHTUSWYxNjNxMTFOwG0> MUSxNkBp NHTtWFlFVVOR MXHlcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= Mnq5NlIyPzlzOUi=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
EGFR / STAT3 ; 

PubMed: 31289542     


Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting.

Cyclin D1 / CDK6 / CDK4 / p-RB / RB; 

PubMed: 31289542     


Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. 

MMP-1 / MMP-3 / MMP-13 / TIMP-1; 

PubMed: 27431944     


Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h.

Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); 

PubMed: 27431944     


Chondrocytes were treated with increasing concentrations of TSA for 24 h.

α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; 

PubMed: 23802098     


Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).

31289542 27431944 23802098
Immunofluorescence
α-C/EBPβ / α-HP1α ; 

PubMed: 21122806     


3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. 

α-HDAC1 ; 

PubMed: 29045501     


MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels.

α-tubulin / acetylated histone 3; 

PubMed: 27957719     


Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.

21122806 29045501 27957719
Growth inhibition assay
Cell viability (A549 cells); 

PubMed: 27571418     


Cytotoxicity of histamine determined by MTT assay in A549 cells.

Cell viability (MDA-MB-231 cells); 

PubMed: 27548148     


The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8.

Cell viability (PC3 cells); 

PubMed: 31289542     


PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.

27571418 27548148 31289542
In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

- Collapse

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

- Collapse
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03901053 Not yet recruiting Device: Reaktiv AFO|Device: PhatBrace AFO Foot Injuries and Disorders Jason Wilken|Minneapolis Veterans Affairs Medical Center|Walter Reed National Military Medical Center|Henry M. Jackson Foundation for the Advancement of Military Medicine|Center for Veterans Research and Education|University of Delaware|Johns Hopkins Bloomberg School of Public Health|University of Iowa June 2019 Not Applicable
NCT03887650 Recruiting Drug: Liposomal Bupivicaine 1.3%|Drug: Bupivacaine 0.5% Post-operative Pain|Total Shoulder Arthroplasty|Osteoarthritis of the Shoulder|Pain Management Hartford Hospital January 14 2019 Phase 4
NCT03838926 Recruiting Drug: Trichostatin A Relapsed or Refractory Hematologic Malignancies Vanda Pharmaceuticals September 27 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID